Artivion Q2 2026: Revenue Up 11% but Net Loss of $(13.5)M on Endospan Deal Costs and Contingent Consideration Charge
AORT sits 44% above its 52-week low of $19.16.
Summary
Artivion's Q2 2026 revenue rose 11% to $125.8 million, but the company reported a $(13.5) million net loss due to Endospan acquisition costs and a non-cash contingent consideration charge. Debt increased to $370 million to fund the deal.
Key Events · Earnings and Guidance · AORT
-
Q2 Revenue Growth of 11%
Total revenues reached $125.8 million, up 11% year-over-year, with aortic stent grafts up 16% and On-X valves up 19%. Constant currency revenue growth was 9%.
-
GAAP Net Loss of $(13.5) Million
The net loss was driven by $11.7 million in Endospan acquisition-related costs (including $10.2 million in transaction bonuses) and an $8.0 million non-cash fair value loss on contingent consideration.
-
Debt Surges to $370 Million
Total principal debt increased to $370 million from $220 million at year-end 2025, primarily due to a $150 million draw on the New Delayed Draw Term Loan Facility to fund the Endospan acquisition. Cash and equivalents stood at $77.3 million with $30 million undrawn on the revolver.
-
Potential €7 Million German Tax Exposure
The company disclosed initial correspondence from German tax authorities regarding intercompany financing arrangements. If the tax authority prevails, the additional exposure would be approximately €7 million, excluding interest and penalties.
Analysis · AORT · Industrial Applications And Services
Artivion posted solid 11% revenue growth to $125.8 million, driven by aortic stent grafts and On-X valves, but swung to a GAAP net loss of $(13.5) million. The loss was largely due to $11.7 million in Endospan acquisition costs and an $8.0 million non-cash fair value loss on contingent consideration. Total debt jumped to $370 million after drawing $150 million to fund the Endospan deal, though liquidity remains adequate with $77.3 million in cash and $30 million undrawn on the revolver. A new risk factor discloses a potential €7 million German tax exposure. The quarter reflects the near-term financial drag of the Endospan integration, offset by strong underlying demand.
At the time of this filing, AORT was trading at $27.52 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $19.16 to $48.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.